| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2012: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
Intraperitoneal (IP) administration of nanomicellar PTX (NK105) significantly reduced peritoneal tumors than conventional PTX formulation with similar systemic toxic effects, suggesting the clinical usefulness of IP-NK105. Peritoneal nodules are covered with fibrous capsule containing many CD31(+) microvessels both in human and mice. After IP-PTX, however, the peripheral vessels were greatly reduced in number with luminal obstruction. These findings strongly suggest that the remarkable efficacy of IP-PTX is partly dependent on the destruction of peripheral tumor vessels. CD90(+) cells in human peritoneum vigorously grew in culture and express CAF characteristics by TGF-b, and IP co-injection with MKN45 significantly enhanced peritoneal metastasis in nude mice. The CD90(+) cells were engrafted in metastatic nodules mainly at the fibrous area. Oral administration of Dasatinib significantly inhibited the development of peritoneal metastasis of MKN45 with reduced fibrillar formation.
|
